Abstract
Corticosteroids reduced mortality rate in patients with coronavirus disease 2019 (COVID-19). Previously, we hypothesized that corticosteroids mitigate the inflammation response resulting in reduced coagulation and thrombosis. In this retrospective study, we included 27 patients with COVID-19 that received high-dose corticosteroids (methylprednisolone 1000 mg i.v. daily for 3 days) for persistent respiratory failure or an excessive inflammation response. We found that inflammation, coagulation, and ventilation parameters improved significantly after methylprednisolone. The viral loads of SARS-CoV-2 remained stable or decreased. These results provides insight into the reduced mortality rate observed in patients with COVID-19 treated with corticosteroids.
Original language | English |
---|---|
Journal | Biomarker Insights |
Volume | 16 |
DOIs | |
Publication status | Published - 1 Jan 2021 |
Bibliographical note
Funding Information:The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Katja Tromp, Philip van der Zee, Jeroen van Kampen, and Henrik Endeman declare no competing interests. Diederik Gommers received speakers fee and travel expenses from Dräger, GE Healthcare (medical advisory board 2009-2012), Maquet, and Novalung (medical advisory board 2015-2018). Casper Rokx reports grants from Research Grants from ZonMW, Federation Medical Specialist, AIDSfonds, Gilead, ViiV, Merck, Janssen-Cilag, personal fees from Advisory board consultancy, speaker’s fee, conference registrations from Gilead, ViiV, outside the submitted work.
Publisher Copyright:
© The Author(s) 2021.